Lanean...

Clinical and comparative utility of afatinib in non-small cell lung cancer

The first targeted agents approved for non-small cell lung cancer (NSCLC) treatment, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib, have an impressive activity in the presence of activating mutations of the EGFR gene. However, all patients deve...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: D’Arcangelo, Manolo, Hirsch, Fred R
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove Medical Press 2014
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4003149/
https://ncbi.nlm.nih.gov/pubmed/24790411
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BTT.S40567
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!